US2019292216A1PendingUtilityA1

Cyclic Di-Nucleotide Induction of Type I Interferon

47
Assignee: UNIV CALIFORNIAPriority: May 3, 2013Filed: Feb 19, 2019Published: Sep 26, 2019
Est. expiryMay 3, 2033(~6.8 yrs left)· nominal 20-yr term from priority
Inventors:Russell E. VanceMing C. HammondDara BurdetteElie J. DinerStephen C. Wilson
A61P 31/12A61P 35/04A61P 35/00A61P 37/04A61K 31/7084C07H 21/02
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions are provided for increasing the production of a type I interferon (IFN) in a cell. Aspects of the methods include increasing the level of a 2′-5′ phosphodiester linkage comprising cyclic-di-nucleotide in a cell in a manner sufficient to increase production of the type I interferon (IFN) by the cell. Also provided are compositions and kits for practicing the embodiments of the methods.

Claims

exact text as granted — not AI-modified
1 .- 86 . (canceled) 
     
     
         87 . A method of treating a subject for a neoplastic disease, the method comprising:
 administering to the subject an anti-neoplastic agent in combination with a 2′-5′ phosphodiester linkage comprising cyclic-di-nucleotide to treat the subject for the neoplastic disease.   
     
     
         88 . The method according to  claim 87 , wherein neoplastic disease is cancer. 
     
     
         89 . The method according to  claim 88 , wherein the anti-neoplastic agent is a chemotherapeutic agent. 
     
     
         90 . The method according to  claim 87 , wherein the subject is a mammal. 
     
     
         91 . The method according to  claim 90 , wherein the mammal is a human. 
     
     
         92 . The method according to  claim 87 , wherein the cyclic-di-nucleotide comprises two 2′-5′ phosphodiester linkages. 
     
     
         93 . The method according to  claim 87 , wherein the cyclic-di-nucleotide comprises a 2′-5′ phosphodiester linkage and a 3′-5′ phosphodiester linkage. 
     
     
         94 . The method according to  claim 87 , wherein the cyclic-di-nucleotide comprises a guanosine nucleoside. 
     
     
         95 . The method according to  claim 87 , wherein the cyclic-di-nucleotide comprises an adenosine nucleoside. 
     
     
         96 . The method according to  claim 87 , wherein the cyclic-di-nucleotide comprises an adenosine and a guanosine nucleoside. 
     
     
         97 . A method of treating a subject for a neoplastic condition, the method comprising:
 administering to the subject a specific binding moiety in combination with a 2′-5′ phosphodiester linkage comprising cyclic-di-nucleotide to treat the subject for the condition.   
     
     
         98 . The method according to  claim 97 , wherein the specific binding moiety is an antibody. 
     
     
         99 . The method according to  claim 97 , wherein neoplastic disease is cancer. 
     
     
         100 . The method according to  claim 97 , wherein the subject is a mammal. 
     
     
         101 . The method according to  claim 100 , wherein the mammal is a human. 
     
     
         102 . The method according to  claim 97 , wherein the cyclic-di-nucleotide comprises two 2′-5′ phosphodiester linkages. 
     
     
         103 . The method according to  claim 97 , wherein the cyclic-di-nucleotide comprises a 2′-5′ phosphodiester linkage and a 3′-5′ phosphodiester linkage. 
     
     
         104 . The method according to  claim 97 , wherein the cyclic-di-nucleotide comprises a guanosine nucleoside. 
     
     
         105 . The method according to  claim 97 , wherein the cyclic-di-nucleotide comprises an adenosine nucleoside. 
     
     
         106 . The method according to  claim 97 , wherein the cyclic-di-nucleotide comprises an adenosine and a guanosine nucleoside.

Join the waitlist — get patent alerts

Track US2019292216A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.